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Available online 31 March 2016Cardiovascular effects are considered frequent during drug safety testing. This investigation aimed to character-
ize the pharmacological response of the conscious telemetered rat in vivomodel to known cardiovascular active
agents. These effects were analyzed using statistical analysis and cloud representationwithmarginal distribution
curves for the contractility index and heart rate as to assess the effect relationship between cardiac variables. Ar-
terial blood pressure, left ventricular pressure, electrocardiogram and body temperature were monitored. The
application of data cloud with marginal distribution curves to heart rate and contractility index provided an in-
teresting tactic during the interpretation of drug-induced changes particularly during selective time resolution
(i.e.marginal distribution curves restricted to Tmax). Taken together, the present data suggests that marginal dis-
tribution curves can be a valuable interpretation strategy when using the rat cardiovascular telemetry model to
detect drug-induced cardiovascular effects. Marginal distribution curves could also be considered during the in-
terpretation of other inter-dependent parameters in safety pharmacology studies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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QT1. Introduction
Cardiovascular monitoring methods using telemetry have be-
come an important component in preclinical safety assessments
over the last decade, providing pharmacologists a simple but valu-
able tool to evaluate drug safety. Telemetry is widely employed to
monitor a variety of cardiovascular parameters such as blood pres-
sure, heart rate (HR), electrocardiogram (ECG), and body tempera-
ture (BT), amongst others, in awake, and freely moving laboratory
animals (Kramer and Kinter, 2003). These systems are typically
employed in regulatory safety pharmacology studies as detailed in
the S7A guideline from the International Conference of Harmoniza-
tion (ICH) (FDA, 2001). The use of telemetry systems in safety as-
sessments has since seen comprehensive implementation and
validation in a variety of preclinical animal models (e.g., rodents,
minipigs, dogs and nonhuman primates) (Authier et al., 2007a,
2007b; Authier et al., 2011; Deveney et al., 1998; Gauvin et al.,
2006; Gelzer and Ball, 1997; Kramer and Kinter, 2003; Markert
et al., 2009; Segreti et al., 2016; Shiotani et al., 2007). While a
broad range of species is available, the rat remains the most45 Armand Frappier, Laval, QC
.
. This is an open access article underfrequently used model for regulatory toxicology assessments (Gad,
2012) and a well-established preclinical cardiovascular safety test-
ing model (Guth, 2007; Jacob, 2010). Apart from the obvious differ-
ence in size, the human and rat heart share similar morphological
and physiological features including similar systolic, mean and
diastolic pressures (Wessels and Sedmera, 2003). Moreover, the
mRNA and expression proﬁle of major cardiac ion channel proteins
in both the atria and ventricle of rats and humans are also similar
with the noted exception of the IKr or human ether-à-go-go-related
gene potassium channel (hERG)-like current which is absent in rats
(Wymore et al., 1997). The use of telemetry cardiovascular monitor-
ing in rats has been employed and successfully validated (Brockway,
Mills, and Kramer, 1998; Deveney et al., 1998; Kramer et al., 2001;
Kramer and Kinter, 2003; Kramer and Remie, 2005) demonstrating
expected cardiovascular and ECG modiﬁcations in responses to
various cardioactive agents. However, the available scientiﬁc
literature with rat telemetry presents limited consideration for
agents inducing inotropic effects. Given this, we aimed to assess
the pharmacodynamics response of telemetered rats to known
pharmacological agents and document the corresponding electro-
cardiographic, hemodynamic, chronotropic and inotropic effects. In
doing so, we provide a better understanding of this pre-clinical
model as well as offer a qualitative approach to beat-to-beat hemo-
dynamic data presentation through the use of marginal distribution
curves.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Cardiovascular positive and negative control drugs.
Drug Method of administration Dose level⁎ (mg/kg)
Saline–water IV/SC–PO 0
Remifentanil IV 0.03
Flecainide IV 16
Dopamine IV 0.1
Pimobendan PO 3, 10, 30
Morphine SC 2, 6, 20
Amrinone PO 10, 30, 100
Atenolol PO 1, 3, 10, 100
Itraconazole PO 10, 30, 100
Administration route: PO, oral; SC, subcutaneous; IV, intravenous (via tail vein).
⁎ Dose selection was based on data previously obtained in conscious rats that were
monitored using telemetry and the scientiﬁc literature available.
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2.1. Statement on use and care of animals
During this investigation, care and use of animals were conducted in
accordancewith principles outlined in the current Guide to the Care and
Use of Experimental Animals published by the Canadian Council on An-
imal Care and theGuide for theCare andUse of Laboratory Animals pub-
lished by the Institute of Laboratory Animal Resources. CiToxLAB's
facility is AAALAC accredited and the procedureswere reviewed and ap-
proved by the Institutional Animal Care and Use Committee prior to
conduct. All procedures were conducted as per Standard Operating Pro-
cedures (SOPs) in place.
2.2. Animals and environment
All animals were housed under standard laboratory conditions with
controlled temperature (21 ± 3 °C), humidity (30%–70%), 12 h light/
dark cycle and 10–15 air changes per hour. Temperature and relative
humidity were monitored continuously. The animals were provided a
standard certiﬁed commercial chow (Harlan Teklad Certiﬁed Global Ro-
dent Diet #2018C) andmunicipal tapwater (which has been exposed to
ultraviolet light and puriﬁed by reverse osmosis) via water bottles ad
libitum. Male Sprague–Dawley rats (Charles River Laboratories, St-
Constant, QC), aged approximately 22 weeks old and weighing approx-
imately 500 g at the beginning of the study were used.
2.3. Surgical instrumentation
2.3.1. General anesthesia and surgical preparation
Penicillin G procaine (Procillin, 300,000 IU/mL, Vetoquinol, Lavaltrie,
Quebec, Canada) and Buprenorphine (Temgesic™, 0.05 mg/kg,
Schering-Plough,WelwynGarden City, Hertfordshire, UK),were admin-
istered by subcutaneous injection prophylactically. General anesthesia
was induced with 2–4% oxygen-isoﬂurane (AErrane™, Baxter Corpora-
tion, Mississauga, ON, Canada) mixture and tracheal intubation was
done with mechanical ventilation at a respiratory rate of 60–85/min
and tidal volume of 2–2.5 ml. Anesthesia was maintained for the dura-
tion of the surgery and rats were closely monitored for the depth of an-
esthesia. Rats were placed on a heated surgical ﬁeld in dorsal
recumbency. The surgical siteswere shaved and the skinwas aseptically
prepared and draped with sterile gauze.
2.3.2. Surgical procedure
All animals underwent surgery for telemetry transmitter implanta-
tion (Data Science International (DSI), Model DSI HD-S21) to monitor
blood pressures, ECG, BT and locomotor activity. Surgeries were per-
formed by a ventralmidline incision on the linea albausing aseptic tech-
niques. The telemetry transmitter was implanted in the left upper
quadrant of abdominal cavity, parallel to the long axis of the body. The
transmitter body was ﬁxed to the abdominal wall using suture ribs
(4–0 polypropylene). Local analgesics, bupivacaine (0.25%, 0.05 ml;
Hospira, Montreal, Quebec, Canada) and lidocaine (20 mg/ml, 0.05 ml;
Lurocaine, Vetoquinol, Lavaltrie, Quebec, Canada), were mixed and
injected subcutaneously at the abdominal incision. The arterial blood
pressure catheterwas inserted into one of the iliac arteries and the elec-
trocardiographic leads were implanted subcutaneously across the ster-
num in a Lead II conﬁguration. For left ventricle pressure catheter
placement, a 3–0 nylon suture was inserted through the xiphoid and
retracted anteriorly to lift the thoracic cavity to allow maximum expo-
sure of the diaphragm. A midline vertical incision was made in the dia-
phragm and a 5–0 propylene suture was passed through each side to
retract the diaphragm, exposing the heart. The apex of the heart was lo-
cated and the left ventricle was subsequently punctured with a 23 G
needle and the tip of the telemetry pressure catheter was inserted
into the ventricle up to the suture rib (approx. 8 mm). The catheterwas ﬁxed in position by tightening the purse string suture and secured.
Once the catheters and lead placements were ﬁnalized, the diaphragm
was sutured ensuring that the catheter exited the thoracic cavity
through the diaphragmat the dorsal end of the incision. Air was aspirat-
ed from the thorax via a 25 G butterﬂy attached to 5ml syringe inserted
in the intercostal space. Negative pressure was re-established prior to
removal of the syringe.
2.3.3. Post-surgical recovery
The abdominal site was ﬂushed with warm saline and the incisions
were closed with absorbable suture material (Novaﬁl 4-0; Covidien,
Saint-Laurent, QC) using simple continuous sutures. The skinwas closed
with discontinuous buried sutures using absorbable suture material
(Vicryl Polyglactin 4-0; Ethicon, Johnson & Johnson, Somerville, NJ,
USA). Instrumented rats were single housed in their home cages and te-
lemetry recordings commenced immediately. Penicillin G procaine and
buprenorphine were subcutaneously injected BID for two days follow-
ing the surgery. Objective end-points to body weight change, mobility
were monitored cautiously for the ﬁrst week post-surgery. If required,
supplemental analgesia (buprenorphine) would be used.
2.4. Experimental design, data acquisition and cardiovascular monitoring
A range of pharmacological agents either negative (i.e. saline (IV/SC)
or water (PO)), or positive (remifentanil, ﬂecainide, dopamine,
pimobendan, morphine, amrinone, atenolol, and itraconazole) control
agents was selected to characterize the rat telemetry model (Table 1).
All treatments were administered precisely at the same time of the
day with at least 3 days of wash-out between doses. The staff was not
allowed to enter the animal room during data acquisition. A negative
control (saline orwater treatment) using the same dose volume and ad-
ministration route was administered 2 days prior to positive control ad-
ministration for within-time comparison with all drugs. Positive
chronotropic and inotropic drugs were selected to induce a battery of
ECG and hemodynamic changes, and for several drugs, different doses
were used for testing potential dose-effect (Table 1). Intravenous injec-
tions and infusions were performed using remote dosing from outside
of the cage with a permanent catheter to avoid artifacts due to handling
stress. Cardiovascular function including systemic arterial blood pres-
sure (diastolic, mean and systolic SABP), left ventricular pressure (sys-
tolic, end diastolic LVP, dP/dt + and contractility index) ECG (HR,
intervals PR, QRS and QT), BT and locomotor activity were monitored
using the radiotelemetry data acquisition programDataquest ART (Ver-
sion 4.39, DSI). Contractility index is deﬁned as dP/dt + divided by the
pressure at that point. ECG analysis was conducted using semi-
automated methods by a single reader to minimize variability
(Authier et al., 2010). Cardiovascular parameters were recorded contin-
uously for a period of at least 1 h pre-dosing and for at least 24 h post-
dosing every 5 s for the duration of the recording. Data were analyzed
and presented using Microsoft Excel (Microsoft Corporation, Redmond,
WA, USA). Marginal distribution curves using beat-to-beat contractility
Fig. 2. Flecainide induced changes in electrocardiographic parameters. A) Percent change
from baseline of the PR interval after intravenous administration of either ﬂecainide
(16 mg/kg) or saline; B) Change in the QRS interval after intravenous administration of
either ﬂecainide (16 mg/kg) or saline. All data was obtained in conscious telemetered
rats. Error bars represent SEM, n = 4.
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ampton, MA, USA) for qualitative data interpretation. Within-time sta-
tistical comparison was completed using an ANOVA for repeated
measures (SAS 9.3, Cary, NC) with Dunnett's post-hoc tests.
3. Results
3.1. Cardiovascular monitoring following drug exposure
3.1.1. Remifentanil
Following intravenous injection of remifentanil (n = 4), there was
an immediate decrease in BT of 4 ± 0.5% (~1.5 °C, p b 0.05) that
persisted for approximately 1.5 h. An immediate and severe bradycardia
also developed shortly after remifentanil administration (slowing of up
to ~71% baseline HR), showing a compensatory increase after 3 min
(p b 0.05) and slowly returning to control HR levels after only 30 min
(Fig. 1). This transient change inHRwas also accompanied by a decrease
in SABP (−15 ± 5% decrease, p b 0.05) and a prolongation of the QRS
interval (up to 2ms, p b 0.05). It is noteworthy tomention that after sa-
line injections, the HR (Fig. 1) and SABP showed a slight increase when
compared with the baseline (pre-dosing) values— an observation con-
sidered as a normal consequence after IV injections of room tempera-
ture saline. No other signiﬁcant change was noted for ECG, LVP and
locomotor activity.
3.1.2. Flecainide
Following intravenous injection of ﬂecainide (n = 4), there was an
immediate and severe decrease in BT of 4 ± 0.5% (~1.4 °C, p b 0.05),
which recovered to baseline levels at approximately 2 h. There were
also noticeable increases in intervals PR (+181% ± 4, p b 0.01), QRS
(+94% ± 4 p b 0.01), and QT (+121% ± 4, p b 0.01) intervals, com-
pared to baseline, the latter two of which occurred periodically for up
to 8 and 16 h post-dosing, respectively (Fig. 2). A mild increase in HR
(+11 ± 1%) was noted but did not reach statistical signiﬁcance.
3.1.3. Dopamine
Single intravenous dosing of dopamine (n = 4) had an immediate
effect on HR leading to an elevation by 18± 4% (p b 0.05) from baseline
(Fig. 3A). Dopamine also largely increased systolic, diastolic and mean
SABP (p b 0.05), as well as pulse pressure by 27 ± 4% (Fig. 3A). Dopa-
mine also presented positive inotropic effects on the contractility
index (Fig. 3B). Marginal distribution curves including the data at 0–
0.25 h post-dosing was optimal to illustrate pharmacodynamics when
compared to the entire 24 h period post-dosing.Fig. 1. Remifentanil induced changes in HR. All data was obtained in conscious
telemetered rats. Error bars represent SEM, n = 4.3.1.4. Pimobendan
After oral administration of pimobendan (n= 8), an immediate de-
crease in BT was observed which reached 35.8 °C (−4 ± 0.4% at
30 mg/kg, p b 0.05) at 3 h post-dosing and progressively returned to
baseline values at 14 h. A progressive decrease in systolic SABP at the
high dose level (30 mg/kg) was also observed, when compared to the
control, which started ~1 h post-dosing, reached nadir at 8 h post-
dosing (−11 ± 4%, p b 0.05) and returning to basal levels thereafter
with total recovery noted at 16 h post-dosing. This effect on systolic
SABP was associated with an increase in HR (+37 ± 3% at 30 mg/kg,
p b 0.05) during the same period. Mild effects were also observed on
HR at both the mid (10 mg/kg) and low (3 mg/kg) doses, but these ef-
fects were not associated with any signiﬁcant decrease in SABP. A
clear dose-dependent increase in dP/dt max (+86 ± 10% at 30 mg/kg,
p b 0.01) and contractility index (+85 ± 7% at 30 mg/kg, p b 0.01)
was noted following administration of pimobendan (Fig. 4A). Maximal
effects are illustrated with marginal distribution curves restricted
around Tmax (Fig. 4A, right) at 2–4 h post-dosing.3.1.5. Morphine
Subcutaneous administration of morphine (n = 9) was associated
with an immediate and dose-dependent increase in BT lasting between
4 and 8 h reaching a maximum of 2.5 ± 0.2 °C (p b 0.01), compared to
the control. A trend (not statistically signiﬁcant) towards dose depen-
dent increases in systolic LVP, systolic, mean and diastolic SABP was
also immediately noticeable after dosing, peaking at approximately
2 h and returning to basal levels at 4 h post-dosing. At the high dose
(20 mg/kg) an increase in HR was observed immediately after dosing
reaching a peak at 3.5 h (+51 ± 5%, p b 0.01) and returning to basal
levels at approximately 10 h post-dosing. A similar, albeit less severe, el-
evation in HR was also observed at 2 and 6 mg/kg, both of which
returned to basal levels at ~6 h post-dosing. The contractility index
(+71 ± 9%, at 20 mg/kg at 4 h post-Rx, p b 0.01) and dP/dt max
(+83± 11%, at 20mg/kg at 4 h post-Rx, p b 0.01) parameters were in-
creased in a dose dependentmanner. Themarginal distribution curve of
morphine's effects on HR and contractility index (Fig. 4B) illustrates a
trend towards dose dependent, positive chronotropic effect (considered
secondary to central nervous system stress) with HR-mediated positive
Fig. 3. Dopamine-induced effects on various cardiovascular parameters. A) Comparison of dopamine-induced changes on various cardiovascular parameters. Error bars represent SEM,
n = 4. HR, heart rate; sSABP, systolic systemic arterial blood pressure; mSABP, mean systemic arterial blood pressure; dSABP, diastolic systemic arterial blood pressure; Pulse, pulse
pressure; B) Marginal distribution curve comparing dopamine-induced changes (green), with respect to saline (red), on the contractility index and heart rate at either 0–24 h post-
dosing (left) or within a 0–0.25 h time window representing Tmax (right). All data was obtained in conscious telemetered rats. * p b 0.05.
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stricted to Tmax (Fig. 4A, right).3.1.6. Amrinone
Oral administration of amrinone (n= 8) was associated with an in-
crease in dP/dtmax (+36±7% at 100mg/kg, p b 0.05) and contractility
index (+31± 8% at 100mg/kg, p b 0.05) with peak effect at 10 h post-
dose. An increase in HR was noted at the high dose with peak effect at
3 h post-dose (+24 ± 5%, p b 0.05). No signiﬁcant effect on SABP wasFig. 4. Marginal distribution curve for heart rate and contractility index following positive in
amrinone- (C) induced changes, with respect to saline, at various dosing levels at either 0–2
was obtained in conscious telemetered rats. Pimobendan and amrinone, n = 8; morphine, n =noted. The marginal distribution curve of amrinone at Tmax (Fig. 4C,
right) showed a clear dose dependent positive inotropic effect.
3.1.7. Atenolol
When compared to control, oral administration of atenolol (n = 9)
at 10 and 100 mg/kg induced a progressive decrease in HR, diastolic
SABP, dP/dt max, contractility index and systolic LVP (Fig. 5). At high
dose (100mg/kg), the peak effect on HR (−32± 2%, p b 0.01), diastolic
SABP (−17 ± 4%, p b 0.01), dP/dt max (−36 ± 3%, p b 0.05) and con-
tractility index (−17± 4%, p b 0.05) was noted around 16 h (960min)otropic agent administration. Curves comparing pimobendan- (A), morphine- (B) and
4 h post-dosing (left) or within a 2–4 h time window representing Tmax (right). All data
9.
Fig. 5.Effect of atenolol on contractility index andheart rate. Curves comparing contractility index (top) andheart rate (bottom) after saline control or atenolol administration at 1, 3, 10 and
100 mg/kg (n = 9). Error bars represent SEM.
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(−10± 4%) was noted at 2 h post-dosing, while HR showed a mild but
long lasting decrease from 2 to 13 h post-dose with a peak effect
(−11 ± 5%) at 9 h post-dosing (Fig. 5). No signiﬁcant effect on HR
and SABP was noted with atenolol at the lower doses (i.e. 1 and
3 mg/kg). When HR and contractility index were presented with mar-
ginal distribution curves (Fig. 6A), atenolol's negative chronotropic ef-
fects were evident at 100 mg/kg at 0–24 h (Fig. 6A, left) and present
for all doses at 2–4 h (Fig. 6A, right) compared to saline.3.1.8. Itraconazole
Unlike the other positive and negative control drugs usedwithin this
study, itraconazole (n = 8) did not yield the expected negative inotro-
pic effects at any dose level tested. Changes were considered to reﬂect
inter-individual variations (Fig. 6B). In this ﬁgure, neither time point(0–24 h nor 2–4 h) showed any noteworthy inotropic effects of
itraconazole at any dose level.4. Discussion
Marginal distribution curves, sometimes referred as border plots, are
distribution curves that are added parallel to scatter plot axes to illus-
trate the data density across the range that is graphically presented.
Marginal distribution curves are seldom used in safety pharmacology
but were applied to various disciplines including statistical astronomy
(Trumpler and Weaver, 1962) and computer science (Guo et al.,
2015). In the current study, we explored the application ofmarginal dis-
tribution curves to safety pharmacology data focusing on cardiac con-
tractility and heart rate relationships. Marginal distribution curves are
typically applied to multivariate functional data with spatially
Fig. 6.Marginal distribution curve for heart rate and contractility index following atenolol and itraconazole administration. Curves comparing atenolol- (A) and itraconazole- (B) induced
changes, with respect to saline, at various dosing levels at either 0–24 h post-dosing (left) or within a 2–4 h time window representing Tmax (right). All data was obtained in conscious
telemetered rats. Atenolol, n = 9; itraconazole, n = 8.
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monly observed in safety pharmacology.
It is common knowledge that unlike other species used in cardiac
safety testing (Nerbonne, 2000), rats possess little to no ventricular
hERG-like current (Wymore et al., 1997) making them unsuitable for
QT interval assessments (Sanguinetti and Tristani-Firouzi, 2006). It re-
mains that a range of other clinically relevant drug-induced cardiovas-
cular effects can be identiﬁed with the rat model such as effects on
arterial blood pressures, HR, ventricular pressures, PR andQRS intervals.
As presented in the result section, expected drug effects were noted in
this rat telemetry model with all positive drugs with the exception of
itraconazole.
Flecainide induced an increase in the atrioventricular conduction
(PR interval) and QRS interval duration (Salerno et al., 1986; Heath
et al., 2011), two clinically relevant ECG parameters in drug safety.
Chronotropic, inotropic and hemodynamic effects of dopamine were
comparable to results observed in isolated rat hearts (Zausig et al.,
2010). These effects were also comparable to results reported in the
non-human primates (Authier et al., 2007a, 2007b) using telemetry.
The typical cardiovascular response to morphine in critically ill pa-
tients is a decrease in HR and arterial blood pressure (Rouby et al.,
1981). Conversely, opioids were reported to increase HR and arterial
pressures when administered to conscious cynomolgus (Authier et al.,
2007a, 2007b) and humans (Glass et al., 1993). Morphine was reported
to increase sympathetic nerve activity in healthy human volunteers
(Carter, Sauder, & Ray, 2002).When studied in healthy volunteers,mor-
phine was reported to induce a biphasic effect on venous tone with an
initial contraction followed by venous relaxationwith a reﬂex reduction
in sympathetic alpha adrenergic tone (Zelis, Mansour, Capone, &
Mason,, 1974). In the current study, morphine induced an increase in
HR, left ventricular contractilitywith a trend for increasing SABP. Similar
effects on systolic SABP had been reported following morphine admin-
istration in rats previously (Amagasa et al., 1996), but the effects on HR
were not reported and left ventricular contractility was not monitored.
The lack of effect on HR may be related to the lower morphine doses
that had been used by Amagasa et al. (1996).
Positive inotropic effects of amrinone were identiﬁed in isolated rat
hearts (Chevalier et al., 1987), in conscious rats (Derakhchan & Vargas,
2015), anesthetized dogs (Pagel, Hettrick, andWarltier, 1993) and con-
scious dogs (Guth et al., 2015). In the current study, dose-dependentpositive chronotropic and inotropic effects of amrinone were identiﬁed
as illustrated bymarginal distribution curves (Fig. 4C). The chronotropic
and inotropic effects of atenolol (3 mg/kg, PO) in conscious rats were
absent when animals were maintained at a room temperature of 30 °C
(Derakhchan & Vargas, 2015). Similarly, our results did not identify
any signiﬁcant effect of atenolol at low doses (i.e. 1 and 3 mg/kg, PO)
on HR or contractility when animals were kept at a room temperature
of 21 °C. In contrast, we observed signiﬁcant negative chronotropic
and inotropic effects of atenolol at higher doses (i.e. 10 and mostly
100 mg/kg, PO) in the same environmental conditions (i.e. room tem-
perature of 21 °C).
The absence of an inotropic effect after itraconazole administration
to conscious rats was previously reported (Qu et al., 2013a). The exact
mechanism for the negative inotropic effects of itraconazole remains
uncertain (Qu et al., 2013b) and the reason for the lack of effects
noted in the rat model could not be fully explained. One hypothesis to
explain the absence of effects is related to the limited bioavailability of
itraconazole when administered orally and the importance of low gas-
tric pH to ensure absorption (Miller et al., 2008).
It remains that the rat model enabled identiﬁcation of inotropic ef-
fects with most drugs used. Some agents used in the current study in-
duce direct positive chronotropic and inotropic effects such as
pimobendan (Duncker et al., 1986) and amrinone, while others agents
such asmorphine were considered to have indirect (i.e. central nervous
systemmediated) positive chronotropic effectswithHRdependent pos-
itive inotropic effects. Negative inotropic effects of atenolol were detect-
ed too.
Chronotropic and inotropic effects may result from changes in
endogenous factors (e.g., epinephrine, norepinephrine, dopamine
or cortisol). The circadian cycle modulates cardiovascular parameters
in all species (Malpas and Purdie, 1990; Wang et al., 1999). Within
this study, circadian inﬂuences were observed amongst all cardiovascu-
lar and ECG parameters as expected. The potentially confounding
effects of the circadian cycle were best controlled by scheduling all
activities precisely at the same time of the day throughout the
experiment.
Pre-clinical models to assess ventricular contractility have received
constant attention by the safety pharmacology community over the
last decade (Adeyemi et al., 2009; Blasi et al., 2012; Cools et al., 2014;
Ju et al., 2015; Markert et al., 2007; Markert et al., 2012; Mooney et al.,
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Wallis, Gharanei, and Maddock, 2015). The reason for this steady inter-
est may be related to the high rate of cardiac toxicity reported to affect
nearly one out of 3 drugs during development (Valentin andHammond,
2008). Recent trends in drug approval will likely maintain these
sustained efforts to characterize pre-clinical contractilitymodels. Oncol-
ogy therapies represented approximately 16% of the total approved
drugs and approximately 33% of the novel drug approvals by the FDA
in 2015 up from approximately 6% and 22%, respectively, in 2014
(FDA, 2016a, 2016b). Of the oncology drugs approved in 2015, approx-
imately 61% (11/18) exhibited cardiac dysfunction as an adverse effect,
a number of which are known to alter cardiac contractility. Several an-
ticancer therapies arewell-known to cause cardiac dysfunction particu-
larly amongst tyrosine kinase inhibitors and anthracycline treatments
(Mellor et al., 2011; Pai and Nahata, 2000; Yeh and Bickford, 2009). On-
cology drugs illustrate the broad range of molecules with cardiotoxicity
liabilities. Small molecules such as doxorubicin (an anthracycline) are
well known to induce a progressive cardiomyopathy (Chatterjee et al.,
2010) and/or direct effects on calciumhomeostasis regulation and func-
tion (Boucek et al., 1997; Olson et al., 2005). Beyond chemotherapeutic
drugs, biologics such as trastuzumab (Herceptin; a monoclonal anti-
body) have also been associated with cardiac dysfunction and de-
creased contractility (McNeil, 1998; Yeh and Bickford, 2009) but the
relevance of the rat model to assess cardiac safety of biologics is often
limited due to limited binding afﬁnity.
Interpretation of cardiovascular safety pharmacology data relies on
statistical analysis but with typical group sizes between n = 4 and
n = 8, the experimental designs sharply contrast with the larger
group sizes that are used in phase 1 clinical trials or thoroughQT studies
(e.g., n = 18 to 56) (Malik et al., 2004; Dubois et al., 2015). In this con-
text, qualitative interpretation of the cardiovascular safety pharmacolo-
gy data remains an important part of the data analysis. An industry
survey revealed that statistical analysis was not included in all safety
pharmacology studies (Lindgren et al., 2008), although a trend towards
generalization of the use of statistical analysiswas noted in recent years.
Beat-to-beat monitoring using telemetry generates substantial amount
of data which are typically averaged for interpretation purposes. Data
bins (i.e., averages over a preset duration) can help reduce the random
variability and the use of super-intervals (i.e. averages over longer
data duration) was successfully applied to interpretation of cardiovas-
cular safety pharmacology data (Sivarajah et al., 2010). The resulting av-
erage values translate into increased assay sensitivity by reducing
random parameter variations. The major risk when using data bins is
to overlook a drug effect shorter than the data bin duration. In such
case, the drug effect is “diluted” with normal data included in the
same data bin. To avoid such problem, the duration of each data bin
needs to be carefully selected to separate altered cardiovascular data
fromnormal/unaltered cardiovascular data. But the timing and duration
of pharmacological effects are unknown when a safety pharmacology
study is designed so selection of the bin interval can be challenging.
Beat-to-beat graphical representation preserves data integrity and
may be a sensitive qualitative data analysis strategy. Beat-to-beat data
presentation has been applied to ECG parameters to assess the dynamic
of QT–RR and QT–TQ interval relationships through quantiﬁcation of
heterogeneity, hysteresis and restitution (Fossa, 2008). Cloud analysis
for beat to beat analysis was also recently applied to large animal telem-
etry data including left ventricular contractility parameters (Buchanan
et al., 2015).While cloud data representation is an interesting approach
to qualitative data evaluation, this approach can suffer from data over-
lap. In brief, cloud density may fail to present data density when the
number of data points reaches a conﬂuent pattern. To overcome this
limitation of cloud data representation, marginal distribution curves
may be an interesting tactic to preserve this dimension of the dataset.
The data from the current study support the potential value of marginal
distribution curves in the qualitative interpretation of rat ventricular
contractility and HR data. Furthermore, marginal distribution curvesmay be considered for other parameters (cardiac or even respiratory)
which exhibit rate dependent correlations.
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